Peptide-Major Histocompatibility Complex presenting Cytomegalovirus and Epstein-Barr Virus epitopes (pMHC-CMV/EBV)

Peptide-Major Histocompatibility Complex (pMHC) molecules presenting Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) epitopes are essential immunological targets for managing latent herpesvirus infections and associated cancers. These complexes are formed when viral proteins are processed into short peptides and loaded onto Human Leukocyte Antigen (HLA) Class I or Class II molecules for presentation on the cell surface (Janeway et al., Immunobiology, 2001). Recognition of these pMHC complexes by the T-cell receptor (TCR) is the primary signal for T-cell activation, allowing the immune system to identify and eliminate virally infected cells (Nature Reviews Immunology, 2002). In immunocompromised individuals, such as hematopoietic stem cell or solid organ transplant recipients, the failure of this surveillance mechanism can lead to life-threatening viral reactivation or EBV-driven malignancies like post-transplant lymphoproliferative disorder (PTLD) (Blood, 2017). Therapeutic interventions targeting these complexes include adoptive T-cell therapies, such as Tabelecleucel, which utilize donor-derived T cells specifically primed to recognize EBV pMHC targets (The Lancet Oncology, 2022). These therapies provide a highly specific approach to restoring viral immunity and treating virus-associated tumors by leveraging the natural specificity of the TCR-pMHC interaction.

Other names

HLA-peptide complexpMHC complexCMV/EBV-specific HLA-peptide complexesViral antigen-MHC complexMHC-restricted viral epitopes

Recognition of the specific viral peptide-HLA complex by T-cell receptors (TCRs) on cytotoxic or helper T cells, leading to the targeted lysis of infected or malignant cells and the release of pro-inflammatory cytokines.